JNJ vs LIVN

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

LIVN presents a stark contrast between poor deterministic health and strong market momentum. The Piotroski F-Score of 2/9 indicates significant fundamental weakness, and the technical trend is currently bearish. However, the company maintains strong gross margins (68.01%) and a low debt-to-equity ratio (0.36), while analysts remain bullish with a target price of $79.64. The valuation appears attractive on a PEG basis (0.72), but the negative net profit margin and ROE suggest operational inefficiencies or significant non-operating losses.